Cyclotron and Radiochemistry

纪念斯隆-凯特林回旋加速器/放射化学资源为放射性核素提供基础设施 五个项目的生产、放射化学合成和放射性抗体制备，以及2 ICMIC更新的发展项目。该资源包括最先进的设施，如 EBCO 19/9回旋加速器和相关的放射化学支持设施，包括热室和引擎盖 位于威尔康奈尔大学医疗中心最先进的共享设施中。这个设施 生产大多数研究放射性核素，包括F-18氟化物和F-18 F-2气体，碳11， 氚-94M、Y-86和碘-124。特别是，成功地生产了大量的 碘124以多种放射性药物的形式存在，是一种标志性的资源产品。另请访问 这一设施、生产FDG和C11蛋氨酸的自动化程序被执行。 斯隆-凯特琳癌症纪念中心还提供包括热细胞在内的放射化学支持设施 中心同位素实验室，以及寿命更长的放射性核素和定制中心合成在 从威尔·康奈尔大学的设施运输过来后，在校园内的设施。产生了各种不同的放射性配体 由资源支持一系列项目，包括使用核苷进行基因表达成像 底物，FEAU和FIAU，同时标记F-18和Lodine-124。此外，新的小分子和 MSKCC斯隆-凯特琳癌症中心也首次产生了抗体 资源，特别是以正电子发射的形式。总共有18种定制的放射性药物 它是人工合成的，将满足ICMIC科学家的特殊需要。其中，预计 所有这些都将准备成适合人类使用的形式。

The Memorial Sloan-Kettering cyclotron/radiochemistry resource provides infrastructure for radionuclide production, radiochemical synthesis, and radio antibody preparation for the five projects, and 2 developmental projects of the ICMIC renewal. The resource includes state-of-the-art facilities, such as the EBCO 19/9 cyclotron and associated radiochemistry support facilities including hot cells and hoods which are located in a state-of-the-art shared facility with Weill Cornell University medical Center. This facility produces most of the research radionuclides including F-18 fluoride and F-18 F-2 gas, carbon 11, technetium-94m, yttrium 86, and lodine-124. In particular, successful production of significant quantities of Iodine124 in a variety of radiopharmaceutical forms is a kind of signature product for the resource. Also at this facility, automated procedures for the production of FDG, and C11 methionine are carried out. Radiochemistry support facilities including hot cells are also available at Memorial Sloan-Kettering cancer central isotope laboratory, and the longer live radionuclides and custom center syntheses are performed in facilities on campus after transport from the Weill Cornell facility. A diverse variety of radioligands produced by the Resource support a broad set of projects, including gene expression imaging with a nucleoside substrates, FEAU and FIAU, labeled with both F-18 and lodine-124. In addition novel small molecules and antibodies have also been produced for the first time at MSKCC Sloan-Kettering cancer center by the Resource, particularly in positron emitting form. A total of 18 custom radiopharmaceuticals have been synthesized and will be available for the special needs of the ICMIC scientists. Of these, it is anticipated that all of these will be prepared in a form suitable for use in man.